CA2593316A1 - Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant - Google Patents

Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant Download PDF

Info

Publication number
CA2593316A1
CA2593316A1 CA002593316A CA2593316A CA2593316A1 CA 2593316 A1 CA2593316 A1 CA 2593316A1 CA 002593316 A CA002593316 A CA 002593316A CA 2593316 A CA2593316 A CA 2593316A CA 2593316 A1 CA2593316 A1 CA 2593316A1
Authority
CA
Canada
Prior art keywords
alkyl
hydrogen
group
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002593316A
Other languages
English (en)
Inventor
Daniel Bichon
Xavier Emonds-Alt
Patrick Gueule
Vincenzo Proietto
Didier Van Broeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi-Aventis
Daniel Bichon
Xavier Emonds-Alt
Patrick Gueule
Vincenzo Proietto
Didier Van Broeck
Sanofi
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9510776A external-priority patent/FR2738819B1/fr
Application filed by Sanofi-Aventis, Daniel Bichon, Xavier Emonds-Alt, Patrick Gueule, Vincenzo Proietto, Didier Van Broeck, Sanofi, Sanofi-Synthelabo filed Critical Sanofi-Aventis
Publication of CA2593316A1 publication Critical patent/CA2593316A1/fr
Abandoned legal-status Critical Current

Links

CA002593316A 1995-09-14 1996-09-13 Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant Abandoned CA2593316A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9510776A FR2738819B1 (fr) 1995-09-14 1995-09-14 Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
FR9510776 1995-09-14
CA002232007A CA2232007A1 (fr) 1995-09-14 1996-09-13 Derives de 1-acyl-3-phenyl-3-(3-piperidinopropyl)piperidine utilises comme antogonistes selectifs du recepteur humain nk3

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002232007A Division CA2232007A1 (fr) 1995-09-14 1996-09-13 Derives de 1-acyl-3-phenyl-3-(3-piperidinopropyl)piperidine utilises comme antogonistes selectifs du recepteur humain nk3

Publications (1)

Publication Number Publication Date
CA2593316A1 true CA2593316A1 (fr) 1997-03-20

Family

ID=38561392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002593316A Abandoned CA2593316A1 (fr) 1995-09-14 1996-09-13 Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant

Country Status (1)

Country Link
CA (1) CA2593316A1 (fr)

Similar Documents

Publication Publication Date Title
US6291672B1 (en) Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
AU2005212510B2 (en) Chemokine receptor antagonists
KR100258373B1 (ko) 다환아민화합물및그의거울상이성질체,그의제조방법및이를함유하는제약학적조성물
KR100238343B1 (ko) 인간 nk3 수용기의 선택적 길항제인 화합물, 및 의약품 및 진단기구로서의 그의 용도
US6294555B1 (en) 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US20010039286A1 (en) 2-aryl indole derivatives and their use as therapeutic agents
HUT76137A (en) Substituted-aliphatic compounds, process for producing them and pharmaceutical compositions containing the same
KR20070007361A (ko) 1-아미노-프탈라진 유도체, 이의 제조 방법 및 치료적 용도
CZ294267B6 (cs) Substituované heterocyklické sloučeniny
NO310913B1 (no) 1-(1,2-disubstituert piperidinyl)-4-substituert piperidinderivater som tachykinin reseptorantagonister
US20080306055A1 (en) Heterocyclic Mchr1 Antagonists And Their Use In Therapy
SG173557A1 (en) Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
JP4459622B2 (ja) ピペリジン誘導体およびケモカイン・レセプター（特にｃｃｒ５）活性モジュレーターとしてのその使用
US6239126B1 (en) Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
US5939411A (en) Piperidine derivatives process for obtaining them and pharmaceutical compositions containing them
WO1995002592A1 (fr) Amides d'acide carboxylique cyclohexane a substitution n-(piperidinyl-1-alkyle) utiles en tant qu'antagonistes du recepteur 5-ht¿1a?
AU3694500A (en) 5-ht1f agonists
NZ307716A (en) 4-[3,5-bis(trifluoromethyl)phenyl]-2-(3,4-dichlorophenyl)-1-[[( substituted heterocyclic)amino]acetyl] piperazine derivatives and medicaments
CA2593316A1 (fr) Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
WO2000035875A1 (fr) Derives d'uree arylpiperidine et aryl-1,2,5,6-tetrahydropyridine presentant une activite de recepteur de 5ht1a
JPH0558999A (ja) カルバミン酸誘導体及びその製造方法
NO318794B1 (no) Alisykliske, acylerte heterosykliske derivater, anvendelse derav og farmasoytiske produkter inneholdende disse
MX2007000814A (es) Derivados de 4-arilmorfolin-3-ona, su preparacion y uso terapeutico de los mismos.
JPWO2005030722A1 (ja) Ｎ−置換−ｎ−（４−ピペリジニル）アミド誘導体
JPH08511276A (ja) 置換された窒素性ヘテロ芳香族化合物の塩、これらの製造方法及びこれらを含有する薬学的組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead